Pramodini Medicare Ltd IPO
Status: Closed
Overview
IPO date
12 Aug 2026 to 14 Aug 2026
Face value
₹ 10 per share
Price
₹ 110 to ₹118 per share
Issue Size
5,851,200 shares
(aggregating up to ₹ 69.04 Cr)
(aggregating up to ₹ 69.04 Cr)
Allotment Date
17 Aug 2026
Listing at
NSE
Issue type
Book Building - SME
Sector
Healthcare
Unlock Stock of the Month
T&C*
Strengths vs Risks of Pramodini Medicare Ltd
Know the pros & cons
Strengths
- Establishing a Strategic presence across various states of India.
- Strengthening Our Network with Diversified Models.
- Technical Capability with robust IT Infrastructure.
- Dedicated Management Team with Significant Industry Experience.
- Track record of revenue and financial performance.
- Diverse Customer cum Patient Base.
Risks
- A significant portion of the company's revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect its business, financial condition and results of operations.
- Concentrated emphasis on radiology services also exposes it to substantial risks that could adversely impact the company's operations, financial performance, and long-term growth prospects.
- The company derives substantial portion of its revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on the company's business, results of operations and financial condition.
- The company is majorly dependent on certain key customers cum patients for a substantial portion of its revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on the company's profitability and results of operations.
- The company derives a significant portion of its revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect the company's business, financial condition and results of operations.
- Failures to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for it and could materially and adversely affect its reputation and results of operations.
- The company relies on its information technology systems in providing the company's diagnostic services and managing its operations, and any disruption to such systems or networks could adversely affect the company's business operations, reputation and financial performance.
- Any inadequacy in packaging, collection of, or failures or delay in the delivery of, specimens to the company's diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect the company's business, results of operations and financial condition.
- The Company is not having any exact comparable Indian peer which have similar business to the Company.
- The company is required to furnish bank guarantees as part of its business under Strategic Partnership with PSU Govt of India. The company's inability to arrange such guarantees or the invocation of such guarantees may adversely affect its cash flows and financial condition.
- The prices that the company can charge for its diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the MOUs entered into with public sector enterprises, state governments and some of private medical establishments.
- The company has not yet placed orders in relation to the capital expenditure requirements of the Company towards purchase of certain medical equipments for its existing and proposed diagnostic centres. In the event of any delay in placing the orders, or if the vendors are unable to provide the equipments in a timely manner, or at all, the same may result in time and cost overruns.
- The company is subject to extensive regulatory requirements governing its operations, and any failures to comply with such requirements may expose it to penalties and adversely affect the company's business, operations and financial condition.
- The company's utilisation of a portion of the Net Proceeds towards unidentified acquisitions is based on management estimates, which have not been independently appraised by a bank or a financial institution and its inability to identify or complete such acquisitions may adversely affect the company's growth and competitiveness.
- Certain licenses for the Company's diagnostic equipment are held in the name of the Company and individual personnel in accordance with the prescribed regulatory format and requirements of Atomic Energy Regulatory Board, and any delay in updating the name of employees in such licenses may affect the Company's ability to use such equipment.
- Certain diagnostic centres have been established and are operated under Public Private Partnership contracts awarded by government agencies through a competitive bidding process. There can be no assurance that the company will qualify for, or that its will successfully compete and win such tenders.
- The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- The company relies on third parties for certain aspects of its operations, and any deficiency in services provided by them could adversely affect the company's business and reputation.
- The Company has negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
- The Company has extended a corporate guarantee in favour of Sri Ram Medicare Private Limited, a promoter group entity, in relation to its borrowings, and any invocation of such guarantee may adversely affect its business, financial condition, cash flows and results of operations; further, such related party arrangements may give rise to conflicts of interest.
- Failures to introduce new tests, services, equipment and technologies could adversely affect the company's business, results of operations and financial condition.
- The company may be unable to retain or recruit trained professionals, which may adversely impact the reputation of the Company and materially and adversely affect its results of operations and cash flows.
- There are certain discrepancies/errors/delay filings noticed in some of the company's corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate or any other law could impact the financial position of the Company to that extent.
- There are certain discrepancies and non-compliances noticed in some of the company's financial reporting and/or records relating to filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- The company may become subject to professional malpractice liability claims, which could be costly and, therefore, could negatively affect its business, results of operations and financial condition.
- The diagnostics industry in India is highly competitive and the company's inability to compete effectively may adversely affect its business, results of operations and financial condition.
- The company has certain contingent liabilities that have not been provided for in the company's financial statements, which if they materialise, may adversely affect its financial condition.
- The Company has entered into related party transactions in the past and may continue to enter into related party transactions in the future, which may potentially involve conflicts of interest with the equity shareholders.
- The company depends on third-parties to purchase diagnosis and imaging equipments, and any failures to continue to do so could adversely affect its business, results of operations and financial condition.
- Although the company's endeavour to ensure compliance with all applicable laws through its internal processes and third-party consultants, there can be no assurance that inadvertent lapses or interpretational differences will not arise in the future. Any such instances may have a material adverse effect on the company's business, financial performance, and operational continuity.
- The company is required to comply with certain restrictive covenants under its financing agreements. Any noncompliance may lead to, amongst others, suspension of further drawdowns, which may adversely affect the company's business, results of operations, financial condition and cash flows.
- Certain of the Company's agreements may be insufficiently stamped and, accordingly, may not be admissible in evidence or enforceable unless the applicable stamp duty and penalties are paid, which could adversely affect the Company's ability to enforce its rights.
- Employee misconduct or failures of the company's internal processes or procedures could harm it by impairing its ability to attract and retain patients and subject it to significant legal liability and reputational harm.
- Failures or malfunction of the company's equipment could adversely affect its ability to conduct the company's operations.
- Disruption to or failures of transportation services for samples or test kits and other materials could materially and adversely affect the company's business and financial results.
- The company is dependent on a number of key personnel, including its senior management and qualified and experienced laboratory professionals, and the loss of, or the company's inability to attract or retain such persons could adversely affect its business, results of operations and financial condition.
- Certain of the Company's registration records contain minor discrepancies in address details, and any delay in rectifying such discrepancies may requires administrative actions and regulatory interactions.
- The Company has received a notice dated November 25, 2020 in relation to non-payment of tax deducted at source, and any adverse outcome or further action by the tax authorities may expose it to liabilities.
- Business interruption at the company's diagnostic centres could result in significant losses and reputational damage to its business.
- Its Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have incurred losses in the past and may incur losses in the future which could have an adverse effect on the company's business and results of operations.
- Financial difficulties of patients or third-party payers may result in payment delays or requires it to write off debts.
- The Company is subject to performance obligations under certain of its contracts, including requirements to furnish performance guarantees and exposure to liquidated damages, and any failures to meet such obligations may result in financial liabilities and impact its operations.
- The company's business is capital intensive. If its experience insufficient cash flows from the company's operations or are unable to borrow to meet its capital requirements, it may materially and adversely affect the company's business and results of operations.
- Certain of the Company's employee and consultant arrangements may not be fully formalised or may not contain all standard contractual provisions.
- The company is subject to data privacy and information security requirements, and any failures to protect patient information or comply with applicable laws may expose it to liabilities and adversely affect the company's business and reputation.
- Certain details relating to one of the company's Independent Director Eshwar Chandra Nandury has not been provided to the Company due to his unwillingness to furnish such information.
- The company has not commissioned an industry report for the disclosures made in the section titled `Industry Overview' and made disclosures on the basis of the data available on the internet and such data has not been independently verified by it.
- The company's operations is conducted from leased premises where certain approvals are dependent on third parties, and any deficiencies in such approvals may affect its ability to operate from such locations.
- The company is significantly dependent on the patients of the healthcare facilities within which its deploy and operates the company's diagnostic centres. A failures to obtain and retain new patients by such facilities or the loss of existing patients could impact its ability to successfully grow the company's business.
- The company's business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in the company's cyber-security.
- The company's insurance coverage may not be sufficient or may not adequately protect it against all material hazards, which may adversely affect its business, results of operations and financial condition.
- The Company's logo "Pramodini Medicare Limited" is not registered with Registrar of Trademark; any infringement of its brand name or failures to get it registered may adversely affect the company's business.
- The company may, in the future, engage in acquisitions and joint ventures. Its may not be able to complete such transactions, and such transactions, if executed, pose significant risks.
- The company is subject to risks arising from interest rate, which could adversely affect its business, financial condition and results of operations.
- Significant differences exist between Indian GAAP and other accounting principles, such as US GAAP and IFRS, which may be material to investors assessments of the Company's financial condition. Its failures to successfully adopt IFRS may have an adverse effect on the price of the company's Equity Shares. The proposed adoption of IFRS could result in the company's financial condition and results of operations appearing materially different than under Indian GAAP.
- In addition to normal remuneration, other benefits and reimbursement of expenses, some of the company's directors (including its Promoters) are interested in the Company to the extent of their shareholding, rent and dividend entitlement in the Company.
- Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.
- After the completion of the Offer, the company's Promoters along with the Promoter Group will continue to control the Company.
- The company's operations is human capital intensive and its operations may be materially adversely affected by strikes, work stoppages or increased salary demands by the company's employees.
- The company has issued Equity Shares during the preceding twelve months at a price which may be below the Offer Price.
- If the company fails to maintain an effective system of internal controls, its may not be able to successfully manage, or accurately report, the company's financial risks. Despite its internal control systems, the company may be exposed to operational risks, including fraud, petty theft and embezzlement, which may adversely affect its reputation, business, financial condition, results of operations and cash flows.
- The company is dependent on government policies and budget allocations for diagnostic centres that its intend to establish in future and the company's overall growth.
- The company's ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company's financing arrangements.
- The company will not receive any proceeds from the Offer for Sale. The Promoter Selling Shareholders will receive the net proceeds from the Offer for Sale.
- The company's Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have been formed to engage in line of business that is synergistic to its business and consequently the interest of these Companies may be in conflict with the interest of the Company in the future.
- The company's directors are associated with other companies which are in businesses similar to its.
- Some of the company's Directors and Promoters have interests its Associate Companies engaged in businesses similar to it.
- The determination of the Price Band is based on various factors and assumptions and the Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares upon listing on the Stock Exchange.
- The company has presented certain supplemental information of its performance and liquidity which is not prepared under or required under AS.
- Pursuant to listing of the Equity Shares, the company may be subject to pre-emptive surveillance measures like Additional Surveillance Measure (ASM) and Graded Surveillance Measures (GSM) by the Stock Exchange in order to enhance market integrity and safeguard the interest of investors.
- Some of the company's Directors do not have experience of being a director of a public listed company.
Pramodini Medicare Ltd Peer Comparison
Understand the company’s industry standing
Pramodini Medicare Limited
Invicta Diagnostic Limited
Krsnaa Diagnostics Limited
Face Value
10
10
5
Standalone / Consolidated
Consolidated
Standalone
Standalone
Total Income Rs. Cr.
---
---
---
EPS-Basis
10.41
4.9
31.3
EPS-Diluted
10.41
4.9
31.3
NAV Per Share
31.84
39.71
302.23
P/E-Basic EPS
---
13.62
16.74
P/E-Diluted EPS
---
---
---
RONW(%)
32.69
9.76
10.35
Latest NAV Period
---
---
---
Latest NAV
---
---
---
How to check the allotment status of Pramodini Medicare Ltd IPO?
Follow the steps
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
Select company from dropdown menu.
Enter details- PAN, Application number or DP client ID
Get your allotment status
Open link to the registrar using this URL (https://evault.kfintech.com/ipostatus/).
IPO reads
Stay updated with the latest IPO developments
February 27, 2025 | 5 min read
₹50.11 Cr Balaji Phosphates IPO Opens Feb 28. Issue Details and SWOT AnalysisRead More
February 25, 2025 | 5 min read
Tata Capital Board Approves ₹15,000 Cr Plus Mega IPO; Tata Investment Shares Soar 8%Read More
February 18, 2025 | 5 min read
Busy Week Ahead: 2 SME IPOs and 9 Market Listings – Get the Complete Details HereRead More
October 25, 2024 | 5 min read
Waaree Energies IPO: GMP Soars 106% Amid 76.34x Subscription – Check Your Allotment Status!Read More
October 22, 2024 | 5 min read
Upcoming IPOs: 9 Public Issues Set to Raise ₹10,984.8 Cr – Key Insights Inside!Read More
October 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
September 6, 2024 | 5 min read
Bajaj Housing Finance IPO: All You Need to KnowRead MoreOctober 17, 2024 | 5 min read
Hyundai IPO Hits a Speed Bump With 42% Subscription On Day 2 : 4 Reasons WhyRead More
August 26, 2024 | 5 min read
Premier Energies IPO: Key Details Ahead of the ₹2,830.40 Cr Issue LaunchRead MoreMore on IPOs
Navigate your way to other IPO resources
Latest videos on IPOs
IPO highlights & details!
FAQs on IPO
Get answers to all your questions here!
The IPO opens on 12 Aug 2026 & closes on 14 Aug 2026.
Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh. Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025.
Company was originally incorporated in the year 2000 with the objective to provide diagnostic services. The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India.
Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.
The Company provide teleradiology services through its registered office situated at Vijayawada which functions on a 24x7 basis throughout the year. It provide healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. The services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
Apart from these, the business operates across four key models mainly the Public Private Partnership (with government hospitals and government teaching hospitals), Private Private Partnership (with private sector hospitals), Strategic Partnership with PSUs (Public Sector Undertakings) Government of India and Private Centres (standalone centre).
The company has filed a Draft Prospectus with SEBI for the IPO by issuing the aggregate of 58,51,200 equity shares of Rs 10 each, which consist a fresh issue of 53,50,000 equity shares and the offer for sale of 5,00,400 equity shares.
Pramodini Medicare Ltd IPO will close on 14 Aug 2026.
- Establishing a Strategic presence across various states of India.
- Strengthening Our Network with Diversified Models.
- Technical Capability with robust IT Infrastructure.
- Dedicated Management Team with Significant Industry Experience.
- Track record of revenue and financial performance.
- Diverse Customer cum Patient Base.
| S.No | Promoters Name | Pre Issue Shares | Pre Issue Percentage | Post Issue Shares | Post Issue Percentage |
|---|---|---|---|---|---|
| 1 | Chalasani Kuldeep Kumar | 8087586 | 48.44 | 7873186 | 35.71 |
| 2 | Chalasani Kavitha | 1634737 | 9.79 | 1491737 | 6.77 |
| 3 | Chalasani Durga Aashritha | --- | --- | --- | --- |
| 4 | Sri Ram Medicare Private Limit | 4587154 | 27.48 | 4444154 | 20.16 |
| 5 | Chalasani Lalithakumari | --- | --- | --- | --- |
- A significant portion of the company's revenue from operations is derived from MOUs with government authorities under Public Private Partnership (PPP) arrangements. Any non-renewal, modification, or termination of such MOUs, or delays or failures in realizing payments from government authorities, may materially and adversely affect its business, financial condition and results of operations.
- Concentrated emphasis on radiology services also exposes it to substantial risks that could adversely impact the company's operations, financial performance, and long-term growth prospects.
- The company derives substantial portion of its revenue from the state of Andhra Pradesh and any loss of business in such regions could have an adverse effect on the company's business, results of operations and financial condition.
- The company is majorly dependent on certain key customers cum patients for a substantial portion of its revenues. Loss of relationship with any of these customers cum patients may have a material adverse effect on the company's profitability and results of operations.
- The company derives a significant portion of its revenue from government authorities (B2G). Any reduction in revenue from them or delays in payments by government authorities, may adversely affect the company's business, financial condition and results of operations.
- Failures to establish and comply with appropriate quality standards when performing diagnostics services could result in litigation and liability for it and could materially and adversely affect its reputation and results of operations.
- The company relies on its information technology systems in providing the company's diagnostic services and managing its operations, and any disruption to such systems or networks could adversely affect the company's business operations, reputation and financial performance.
- Any inadequacy in packaging, collection of, or failures or delay in the delivery of, specimens to the company's diagnostic centres could compromise or destroy the integrity of such specimens, which could adversely affect the company's business, results of operations and financial condition.
- The Company is not having any exact comparable Indian peer which have similar business to the Company.
- The company is required to furnish bank guarantees as part of its business under Strategic Partnership with PSU Govt of India. The company's inability to arrange such guarantees or the invocation of such guarantees may adversely affect its cash flows and financial condition.
- The prices that the company can charge for its diagnostic services are dependent on recommended or mandatory fees fixed under the terms of the MOUs entered into with public sector enterprises, state governments and some of private medical establishments.
- The company has not yet placed orders in relation to the capital expenditure requirements of the Company towards purchase of certain medical equipments for its existing and proposed diagnostic centres. In the event of any delay in placing the orders, or if the vendors are unable to provide the equipments in a timely manner, or at all, the same may result in time and cost overruns.
- The company is subject to extensive regulatory requirements governing its operations, and any failures to comply with such requirements may expose it to penalties and adversely affect the company's business, operations and financial condition.
- The company's utilisation of a portion of the Net Proceeds towards unidentified acquisitions is based on management estimates, which have not been independently appraised by a bank or a financial institution and its inability to identify or complete such acquisitions may adversely affect the company's growth and competitiveness.
- Certain licenses for the Company's diagnostic equipment are held in the name of the Company and individual personnel in accordance with the prescribed regulatory format and requirements of Atomic Energy Regulatory Board, and any delay in updating the name of employees in such licenses may affect the Company's ability to use such equipment.
- Certain diagnostic centres have been established and are operated under Public Private Partnership contracts awarded by government agencies through a competitive bidding process. There can be no assurance that the company will qualify for, or that its will successfully compete and win such tenders.
- The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
- The company relies on third parties for certain aspects of its operations, and any deficiency in services provided by them could adversely affect the company's business and reputation.
- The Company has negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
- The Company has extended a corporate guarantee in favour of Sri Ram Medicare Private Limited, a promoter group entity, in relation to its borrowings, and any invocation of such guarantee may adversely affect its business, financial condition, cash flows and results of operations; further, such related party arrangements may give rise to conflicts of interest.
- Failures to introduce new tests, services, equipment and technologies could adversely affect the company's business, results of operations and financial condition.
- The company may be unable to retain or recruit trained professionals, which may adversely impact the reputation of the Company and materially and adversely affect its results of operations and cash flows.
- There are certain discrepancies/errors/delay filings noticed in some of the company's corporate records relating to forms filed with the Registrar of Companies and other provisions of Companies Act, 2013. Any penalty or action taken by any regulatory authorities in future, for non-compliance with provisions of corporate or any other law could impact the financial position of the Company to that extent.
- There are certain discrepancies and non-compliances noticed in some of the company's financial reporting and/or records relating to filing of returns and deposit of statutory dues with the taxation and other statutory authorities.
- The company may become subject to professional malpractice liability claims, which could be costly and, therefore, could negatively affect its business, results of operations and financial condition.
- The diagnostics industry in India is highly competitive and the company's inability to compete effectively may adversely affect its business, results of operations and financial condition.
- The company has certain contingent liabilities that have not been provided for in the company's financial statements, which if they materialise, may adversely affect its financial condition.
- The Company has entered into related party transactions in the past and may continue to enter into related party transactions in the future, which may potentially involve conflicts of interest with the equity shareholders.
- The company depends on third-parties to purchase diagnosis and imaging equipments, and any failures to continue to do so could adversely affect its business, results of operations and financial condition.
- Although the company's endeavour to ensure compliance with all applicable laws through its internal processes and third-party consultants, there can be no assurance that inadvertent lapses or interpretational differences will not arise in the future. Any such instances may have a material adverse effect on the company's business, financial performance, and operational continuity.
- The company is required to comply with certain restrictive covenants under its financing agreements. Any noncompliance may lead to, amongst others, suspension of further drawdowns, which may adversely affect the company's business, results of operations, financial condition and cash flows.
- Certain of the Company's agreements may be insufficiently stamped and, accordingly, may not be admissible in evidence or enforceable unless the applicable stamp duty and penalties are paid, which could adversely affect the Company's ability to enforce its rights.
- Employee misconduct or failures of the company's internal processes or procedures could harm it by impairing its ability to attract and retain patients and subject it to significant legal liability and reputational harm.
- Failures or malfunction of the company's equipment could adversely affect its ability to conduct the company's operations.
- Disruption to or failures of transportation services for samples or test kits and other materials could materially and adversely affect the company's business and financial results.
- The company is dependent on a number of key personnel, including its senior management and qualified and experienced laboratory professionals, and the loss of, or the company's inability to attract or retain such persons could adversely affect its business, results of operations and financial condition.
- Certain of the Company's registration records contain minor discrepancies in address details, and any delay in rectifying such discrepancies may requires administrative actions and regulatory interactions.
- The Company has received a notice dated November 25, 2020 in relation to non-payment of tax deducted at source, and any adverse outcome or further action by the tax authorities may expose it to liabilities.
- Business interruption at the company's diagnostic centres could result in significant losses and reputational damage to its business.
- Its Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have incurred losses in the past and may incur losses in the future which could have an adverse effect on the company's business and results of operations.
- Financial difficulties of patients or third-party payers may result in payment delays or requires it to write off debts.
- The Company is subject to performance obligations under certain of its contracts, including requirements to furnish performance guarantees and exposure to liquidated damages, and any failures to meet such obligations may result in financial liabilities and impact its operations.
- The company's business is capital intensive. If its experience insufficient cash flows from the company's operations or are unable to borrow to meet its capital requirements, it may materially and adversely affect the company's business and results of operations.
- Certain of the Company's employee and consultant arrangements may not be fully formalised or may not contain all standard contractual provisions.
- The company is subject to data privacy and information security requirements, and any failures to protect patient information or comply with applicable laws may expose it to liabilities and adversely affect the company's business and reputation.
- Certain details relating to one of the company's Independent Director Eshwar Chandra Nandury has not been provided to the Company due to his unwillingness to furnish such information.
- The company has not commissioned an industry report for the disclosures made in the section titled `Industry Overview' and made disclosures on the basis of the data available on the internet and such data has not been independently verified by it.
- The company's operations is conducted from leased premises where certain approvals are dependent on third parties, and any deficiencies in such approvals may affect its ability to operate from such locations.
- The company is significantly dependent on the patients of the healthcare facilities within which its deploy and operates the company's diagnostic centres. A failures to obtain and retain new patients by such facilities or the loss of existing patients could impact its ability to successfully grow the company's business.
- The company's business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in the company's cyber-security.
- The company's insurance coverage may not be sufficient or may not adequately protect it against all material hazards, which may adversely affect its business, results of operations and financial condition.
- The Company's logo "Pramodini Medicare Limited" is not registered with Registrar of Trademark; any infringement of its brand name or failures to get it registered may adversely affect the company's business.
- The company may, in the future, engage in acquisitions and joint ventures. Its may not be able to complete such transactions, and such transactions, if executed, pose significant risks.
- The company is subject to risks arising from interest rate, which could adversely affect its business, financial condition and results of operations.
- Significant differences exist between Indian GAAP and other accounting principles, such as US GAAP and IFRS, which may be material to investors assessments of the Company's financial condition. Its failures to successfully adopt IFRS may have an adverse effect on the price of the company's Equity Shares. The proposed adoption of IFRS could result in the company's financial condition and results of operations appearing materially different than under Indian GAAP.
- In addition to normal remuneration, other benefits and reimbursement of expenses, some of the company's directors (including its Promoters) are interested in the Company to the extent of their shareholding, rent and dividend entitlement in the Company.
- Any variation in the utilisation of the Net Proceeds would be subject to certain compliance requirements, including prior shareholders' approval.
- After the completion of the Offer, the company's Promoters along with the Promoter Group will continue to control the Company.
- The company's operations is human capital intensive and its operations may be materially adversely affected by strikes, work stoppages or increased salary demands by the company's employees.
- The company has issued Equity Shares during the preceding twelve months at a price which may be below the Offer Price.
- If the company fails to maintain an effective system of internal controls, its may not be able to successfully manage, or accurately report, the company's financial risks. Despite its internal control systems, the company may be exposed to operational risks, including fraud, petty theft and embezzlement, which may adversely affect its reputation, business, financial condition, results of operations and cash flows.
- The company is dependent on government policies and budget allocations for diagnostic centres that its intend to establish in future and the company's overall growth.
- The company's ability to pay dividends in the future will depends on its earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the company's financing arrangements.
- The company will not receive any proceeds from the Offer for Sale. The Promoter Selling Shareholders will receive the net proceeds from the Offer for Sale.
- The company's Group Companies namely, Infer Radiological and Imaging Services Private Limited and Vista Pramodini Medicare Private Limited have been formed to engage in line of business that is synergistic to its business and consequently the interest of these Companies may be in conflict with the interest of the Company in the future.
- The company's directors are associated with other companies which are in businesses similar to its.
- Some of the company's Directors and Promoters have interests its Associate Companies engaged in businesses similar to it.
- The determination of the Price Band is based on various factors and assumptions and the Offer Price of the Equity Shares may not be indicative of the market price of the Equity Shares upon listing on the Stock Exchange.
- The company has presented certain supplemental information of its performance and liquidity which is not prepared under or required under AS.
- Pursuant to listing of the Equity Shares, the company may be subject to pre-emptive surveillance measures like Additional Surveillance Measure (ASM) and Graded Surveillance Measures (GSM) by the Stock Exchange in order to enhance market integrity and safeguard the interest of investors.
- Some of the company's Directors do not have experience of being a director of a public listed company.
The Issue type of Pramodini Medicare Ltd is Book Building - SME.
The minimum application for shares of Pramodini Medicare Ltd is 2400.
The total shares issue of Pramodini Medicare Ltd is 5851200.
Initial public offer of 58,51,200 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Pramodini Medicare Limited ("The Company" or "Pramodini" or "The Issuer") at an offer price of Rs. 118 per equity share for cash, aggregating to Rs. 69.04 Crores comprising of fresh offer of 53,50,800 equity shares aggregating to Rs. 63.14 Crores ("Fresh Issue") and an offer for sale of 5,00,400 equity shares by Chalasani Kuldeep Kumar, Chalasani Kavitha and Sri Ram Medicare Private Limited ("Promoter Selling Shareholders") aggregating to Rs. 5.90 Crores ("Offer For Sale") ("Public Offer"). The offer includes a reservation of 3,36,000 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 118 per equity share for cash, aggregating Rs. 3.96 Crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. Net offer of 55,15,200 equity shares of face value of Rs.10/-each, at an offer price of Rs. 118 per equity share for cash, aggregating Rs. 65.08 Crores is herein after referred to as the "Net Offer". The public offer and net offer will constitute 26.54% and 25.02% respectively of the post- offer paid-up equity share capital of the company.
Price Band: Rs. 118/- per equity share of face value of Rs. 10/- each.
The floor price is 11.80 times of the face value of the equity shares.
Bids can be made for a minimum of 1,200 equity shares and in multiples of 1,200 equity shares thereafter.